{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-133141","form_type":"8-K","ticker":null,"cik":"0001827087","company_name":"Vigil Neuroscience, Inc.","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.453605+00:00","generated_at":"2026-06-02T19:51:27.940690+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Vigil Neuroscience reports Q1 net loss $19.9M; completes enrollment for Phase 2 ALSP trial, data in Q3 2024","bullets":["Cash, cash equivalents & marketable securities $101.6M as of Mar 31, 2024; expected to fund operations into H2 2025.","Completed enrollment for Phase 2 IGNITE trial of iluzanebart in ALSP with 20 patients, exceeding planned 15.","Next data readout from Phase 2 IGNITE planned for Q3 2024, including 12-month data from 20 mg/kg cohort and 6-month from 40 mg/kg.","Phase 1 trial of VG-3927 for Alzheimer's ongoing; interim healthy volunteer data expected mid-2024.","Appointed Petra Kaufmann as Chief Medical Officer; she brings over 25 years of neurology drug development experience."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-133141","json":"https://secwatch.observer/filing/0001193125-24-133141.json","markdown":"https://secwatch.observer/filing/0001193125-24-133141.md","text":"https://secwatch.observer/filing/0001193125-24-133141.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1827087/000119312524133141/0001193125-24-133141-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1827087/000119312524133141/d825217d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T19:51:27.940690+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"626f6db3181cbaa8fcd7793dd04bf820094afacd","claim":"Vigil Neuroscience, Inc. reported First quarter ended March 31, 2024 results: net income Loss from operations for the first quarter ended March 31, 2024 were $19.9 million.","evidence_excerpt":"Loss from operations for the first quarter ended March 31, 2024 were $19.9 million, compared to $19.8 million for the same period in 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1827087/000119312524133141/0001193125-24-133141-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"First quarter ended March 31, 2024"},{"label":"Net income","value":"Loss from operations for the first quarter ended March 31, 2024 were $19.9 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}